Epidemiology of nosocomial candidaemia in a university hospital: A 12-year study

Epidemiology and Infection

Volumn 138, Issue 9, 2010, Pages 1328-1335

  Gurcuoglu E ^a   Ener, B ^a   Akalin, H ^a   Sinirtas M ^a   Evci, C ^a   Akcaglar S ^a   Yilmaz, E ^a   Heper, Y ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Candidaemia; epidemiology; nosocomial; university hospital

Indexed keywords

FLUCONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGE DISTRIBUTION; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; EPIDEMIOLOGICAL DATA; FUNGUS ISOLATION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; NONHUMAN; RETROSPECTIVE STUDY; SPECIES DISTRIBUTION; TERTIARY HEALTH CARE; TREND STUDY; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL; CANDIDA; CANDIDIASIS; CHI SQUARE DISTRIBUTION; CLASSIFICATION; CROSS INFECTION; INCIDENCE; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHI-SQUARE DISTRIBUTION; CROSS INFECTION; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; TURKEY;

EID: 77956632184     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268809991531     Document Type: Article

References (35)

1. Hazen KC, Howell SA. Candida, Cryptococcus, and other yeasts of medical importance. In: Baron EJ, Landry ML, Jorgensen JH, Pfaller MA, eds. Manual of Clinical Microbiology, 9th edn. Washington, DC: ASM Press, 2007, pp. 1762-1788.
2. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill nonimmunosuppressed patients. Lancet Infectious Diseases 2003;3:685-702.
3. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clinical Microbiology Reviews 1996;9:499-511.
4. Wisplinghoff H, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases 2004;39:309-317.
5. Diekema DJ, et al. Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infection Control and Hospital Epidemiology 2004;25:624-626.
6. Tortorano AM, et al. Epidemiology of candidemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. European Journal of Clinical Microbiology and Infectious Diseases 2004;23:317-322.
7. Puzniak L, et al. Has the epidemiology of nosocomial candidemia changed? Infection Control and Hospital Epidemiology 2004;25:628-633.
8. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clinical Infectious Diseases 2006;43:3-14.
9. Viudes A, et al. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. European Journal of Clinical Microbiology and Infectious Diseases 2002;21:767-774.
10. Xess I, et al. Epidemiology of candidemia in a tertiary care centre of north India: 5-year study. Infection 2007;35:256-259.
11. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in non-neutropenic patients. Annals of Pharmacotherapy 2007;41:568-573.
12. Bassetti M, et al. Incidence, risk factors, and predictors of outcome of candidemia: survey in 2 Italian university hospitals. Diagnostic Microbiology and Infectious Diseases 2007;58:325-331.
13. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd edn, Document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
14. de Pauw B, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases 2008;46:1813-1821.
15. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clinical Microbiology Reviews 2007;20:133-163.
16. Yapar N, et al. Nosocomial bloodstream infections associated with Candida species in a Turkish university hospital. Mycoses 2005;49:134-138.
17. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Current Infectious Diseases Report 2005;7:429-439.
18. Almirante B, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population based surveillance, Barcelona, Spain, from 2002 to 2003. Journal of Clinical Microbiology 2005;43:1829-1835.
19. Lagrou K, et al. Fungemia at a tertiary care hospital: incidence, therapy, distribution and antifungal susceptibility of causative species. European Journal of Clinical Microbiology and Infectious Diseases 2007;26:541-547.
20. Colombo AL, et al. Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. Journal of Clinical Microbiology 2006;44:2816-2823.
21. Chen YC, et al. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. Journal of Antimicrobial Chemotherapy 2003;52:71-77.
22. Banerjee SN, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. American Journal of Medicine 1991;91:86-89.
23. Rangel-Frausto MS, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clinical Infectious Diseases 1999;29:253-258.
24. Celebi S, et al. Nosocomial candidemia in children: results of a 9-year study. Mycoses 2007;52:248-257.
25. Horvath LL, et al. Direct comparison of the BACTEC 9320 and BacT/ALERT3D automated blood culture systems for Candida growth detection. Journal of Clinical Microbiology 2004;42:115-118.
26. Pfaller MA, et al. Trends in species distribution and susceptibility to fluconazole among bloodstream isolates of Candida species in the United States. Diagnostic Microbiology and Infectious Diseases 1999;33:217-222.
27. Hajjeh RA, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. Journal of Clinical Microbiology 2004;42:1519-1527.
28. Cuenca-Estrella M, et al. Antifungal susceptibilities of Candida species isolated from blood in Spain and Argentina, 1996-1999. Journal of Antimicrobial Chemotherapy 2002;49:981-987.
29. White MH. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clinical Infectious Diseases 1997;24:1129-1130.
30. Kunova A, et al. Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. Clinical Infectious Diseases 1995;21:226-227.
31. Iwen PC, et al. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clinical Infectious Diseases 1995;20:342-347.
32. Bakir M, et al. Epidemiology of candidemia in a Turkish tertiary care hospital. APMIS 2006;114:601-610.
33. Pfaller MA, et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13, 338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute - recommended broth microdilution methods. Journal of Clinical Microbiology 2007;45:70-75.
34. Rex JH, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clinical Microbiological Reviews 2001;14:643-58.
35. St-Germain G, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. Journal of Clinical Microbiology 2001;39:949-53.